-
- Zhenlong Xin
- State Key Laboratory of Cancer Biology Department of Gastroenterology Xijing Hospital The Fourth Military Medical University Xi'an China
-
- Shuai Jiang
- Department of Aerospace Medicine The Fourth Military Medical University Xi'an China
-
- Peng Jiang
- Department of Orthopaedics The 82th Hospital of PLA Huaian China
-
- Xiaolong Yan
- Department of Thoracic Surgery Tangdu Hospital The Fourth Military Medical University Xi'an China
-
- Chongxi Fan
- Department of Thoracic Surgery Tangdu Hospital The Fourth Military Medical University Xi'an China
-
- Shouyin Di
- Department of Thoracic Surgery Tangdu Hospital The Fourth Military Medical University Xi'an China
-
- Guiling Wu
- Department of Biomedical Engineering The Fourth Military Medical University Xi'an China
-
- Yang Yang
- Department of Biomedical Engineering The Fourth Military Medical University Xi'an China
-
- Russel J. Reiter
- Department of Cellular and Structural Biology UT Health Science Center San Antonio TX USA
-
- Gang Ji
- State Key Laboratory of Cancer Biology Department of Gastroenterology Xijing Hospital The Fourth Military Medical University Xi'an China
書誌事項
- 公開日
- 2015-03-23
- 権利情報
-
- http://onlinelibrary.wiley.com/termsAndConditions#vor
- DOI
-
- 10.1111/jpi.12227
- 公開者
- Wiley
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>Gastrointestinal cancer is a disease that affects the population worldwide with high morbidity and mortality. Melatonin, an endogenously produced molecule, may provide a defense against a variety of cancer types. In particular, the ability of melatonin to inhibit gastrointestinal cancer is substantial. In this review, we first clarify the relationship between the disruption of the melatonin rhythm and gastrointestinal cancer (based on epidemiologic surveys and animal and human studies) and summarize the preventive effect of melatonin on carcinogenesis. Thereafter, the mechanisms through which melatonin exerts its anti‐gastrointestinal cancer actions are explained, including inhibition of proliferation, invasion, metastasis, and angiogenesis, and promotion of apoptosis and cancer immunity. Moreover, we discuss the drug synergy effects and the role of melatonin receptors involved in the growth‐inhibitory effects on gastrointestinal cancer. Taken together, the information compiled here serves as a comprehensive reference for the anti‐gastrointestinal cancer actions of melatonin that have been identified to date and will hopefully aid in the design of further experimental and clinical studies and increase the awareness of melatonin as a therapeutic agent in cancers of the gastrointestinal tract.</jats:p>
収録刊行物
-
- Journal of Pineal Research
-
Journal of Pineal Research 58 (4), 375-387, 2015-03-23
Wiley
